






PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference TK-80	FOR FURTHER ACT	ION	See Form PCT/IPEA/416			
International application No.	International filing date	(day/month/year)	Priority date (day/month/year)			
PCT/JP2003/010030	07 August 2003 (09 August 2002 (09.08.2002)			
International Patent Classification (IPC) or national classification and IPC A61K 31/565, 9/70, 47/14, 47/16, 47/32, A61P 3/06, 9/10, 15/12, 19/10, 25/28, 43/00						
Applicant TEIKOKU SEIYAKU CO.,LTD.						
This report is the international preli Authority under Article 35 and tran	minary examination reports	t, established by this cording to Article 3	s International Preliminary Examining 6.			
2. This REPORT consists of a total of3 sheets, including this cover sheet.						
	and the market					
a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:						
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).						
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.						
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the						
Administrative Instructions). 4. This report contains indications relating to the following items:						
Box No. I Basis of the report						
Box No. II Priority						
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
Box No. IV Lack of unity of invention						
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
Box No. VI Certain documents cited						
Box No. VII Certain defe	Box No. VII Certain defects in the international application					
Box No. VIII Certain observations on the international application						
Date of submission of the demand		Date of completio	n of this report			
13 February 2004 (13	.02.2004)	13 8	September 2004 (13.09.2004)			
Name and mailing address of the IPEA/J	P	Authorized office	•			
Food-ilo No		Telephone No.				






PCT/JP2003/010030

BOX IAO.	Basis of the report	
	egard to the language, this report is based on the international application in the langurise indicated under this item.	
	This report is based on translations from the original language into the following I which is language of a translation furnished for the purpose of:	anguage,
	international search (under Rules 12.3 and 23.1(b))	
	publication of the international application (under Rule 12.4)	
	international preliminary examination (under Rules 55.2 and/or 55.3)	
furnis	pages* received by this Authority on pages* received by this Authority on	eplacement sheets which have been to in this report as "originally filed" , as originally filed/furnished, as originally filed/furnished ther with any statement) under Article 19
	the drawings:	, as originally filed/furnished
	pages received by this Authority on	, as originarly most remainder
	pages* received by this Authority on	
	a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence	uence Listing.
3. 🗌	The amendments have resulted in the cancellation of:	
	the description, pages	
	the claims, Nos.	
	the drawings, sheets/figs	
	the sequence listing (specify):	
	any table(s) related to sequence listing (specify):	
	mily tubio(a) totaled to doquened monig (-persy)).	
4.	This report has been established as if (some of) the amendments annexed to this remade, since they have been considered to go beyond the disclosure as filed, as (Rule 70.2(c)). the description, pages	eport and listed below had not been indicated in the Supplemental Box
* If it	em 4 applies, some or all of those sheets may be marked "superseded."	





INTERNATIONAL PRELIM					
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
. Statement	a	2.4	YES		
Novelty (N)	Claims -	3,4	NO		
	Claims	1, 2, 5			
Inventive step (IS)	Claims		YES		
	Claims	1-5	NO NO		
. Industrial applicability (IA)	Claims		YES		
	Claims	. 1-5	NO		
2. Citations and explanations (Rule 7) Document 1: EP, 435200, A2 Document 3: EP, 531938, A2 Document 5: WO, 00/38659 Document 7: JP, 9-315957, A2 Document 9: WO, 97/03698 Document 11: WO, 90/0673 Document 13: WO, 95/1789	2 l , A1 A , A1 6, A1	Document 2: EP, 421454, A2 Document 4: JP, 9-176049, A Document 6: WO, 00/25792, A: Document 8: JP, 2000-63267, A Document 10:JP, 7-10759, A Document 12: JP, 7-101864, A	1		

Explanation:

Documents 1-4 cited in the ISR describe a patch for external use which has a hormone such as estradiol as the active ingredient, comprises an acrylic adhesive containing isocyanate crosslinking agent, and has a polyester film and other films, etc. Also, the blending quantity for each ingredient and the film thickness can be appropriately decided by a party skilled in the art based on the use and medicinal benefits. Therefore, the inventions described in claims 1, 2 and 5 do not appear to be novel or to be novel.

Because documents 1-13 do not describe the inventions described in claims 3 and 4, these inventions appear to be novel.

Because documents 5-13 describe a noretisteron as an active ingredient, crotamiton, oleic acid, and myristic acid isopropyl as absorption promoting agent and solvent, using these does not require any particular creativity.

Therefore, the inventions described in claims 3 and 4 do not appear to involve an inventive step.